{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"45.29","value":"22.1"},{"groupId":"OG001","spread":"62.08","value":"10.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"317"},{"groupId":"OG001","value":"157"}],"units":"Participants"}],"description":"The ACRn is calculated for each participant by taking the lowest percentage improvement in (1) swollen joint count or (2) tender joint count or (3) the median of the remaining 5 components of the ACR response (participant's assessment of disease activity; participant's global assessment of pain; physician's assessment of disease activity; participant's assessment of physical function; an acute phase reactant value - CRP). A positive ACRn Score indicates an improvement.","dispersionType":"Standard Deviation","groups":[{"description":"1000 mg rituximab intravenous initial treatment on day 1 and day 15 plus 10-25 mg/week methotrexate followed by re-treatment during weeks 24 -40 consisting of two additional doses of 1000 mg rituximab 14 days apart plus 10-25 mg/week methotrexate.","id":"OG000","title":"Arm A: Rituximab Re-treatment"},{"description":"1000 mg rituximab initial treatment on day 1 and day 15 plus 10-25 mg/wk methotrexate followed by re-treatment during weeks 24 -40 consisting of two doses of placebo 14 days apart plus 10-25 mg/wk methotrexate.","id":"OG001","title":"Arm B: Placebo Re-treatment"}],"paramType":"MEAN","populationDescription":"Participants from the Intent-to-treat population, that includes all participants randomized to Retreatment, with data available for analyses.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 48","title":"ACRn in Retreated Subjects at Week 48","type":"SECONDARY","unitOfMeasure":"Score on a scale"}